DL-Laudanosoline hydrobromide trihydrate

CAS : 485-33-6

Ref. 3D-FL137896

Informations sur le produit

• Nom: DL-Laudanosoline hydrobromide trihydrate
• Synonymes: (1R)-1-(3,4-dihydroxybenzyl)-6,7-dihydroxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium, (1S)-1-(3,4-dihydroxybenzyl)-6,7-dihydroxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium, (RS)-Laudanosoline, (±)-Laudanosoline, 1-(3,4-Dihydroxybenzyl)-2-Methyl-1,2,3,4-Tetrahydroisoquinoline-6,7-Diol Hydrobromide Trihydrate, 1-[(3,4-Dihydroxyphenyl)methyl]-1,2,3,4-tetrahydro-2-methyl-6,7-isoquinolinediol, 6,7-Isoquinolinediol, 1-(3,4-dihydroxybenzyl)-1,2,3,4-tetrahydro-2-methyl-, 6,7-Isoquinolinediol, 1-[(3,4-dihydroxyphenyl)methyl]-1,2,3,4-tetrahydro-2-methyl-, <span class="text-smallcaps">DL</span>-Laudanosoline, DL-6,7-dimethoxy-1-((3,4-dimethoxyphenyl)methyl)-2-methylisoquinoline hydrobromide trihydrate, DL-laudanosine hydrobromide trihydrate
• CAS: 485-33-6

Description

Laudanosoline is an alkaloid that belongs to the class of bisbenzylisoquinoline alkaloids. It has antioxidative properties and can be used as a chemical biology tool for studying enzymes. Laudanosoline is synthesized from the amino acid tyrosine by a hydroxylation reaction, which occurs on the hydroxyl group at position C-3. The enzyme responsible for this reaction is called lysine acetyltransferase. The synthesis of laudanosoline can also be achieved through a more complex enzymatic pathway, which includes oxidative decarboxylation and methylation reactions with co-factors such as pyridoxal phosphate (PLP). Laudanosoline has been shown to inhibit neuronal degeneration in mice models and has been investigated as a potential drug for neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease.
Laudanosoline inhibits acetylcholinesterase, an enzyme that

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 436.29 g/mol
• Formule: C₁₇H₁₉NO₄·HBr·3H₂O
• Degré de pureté: Min. 95%